Is Owens & Minor, Inc. overvalued or undervalued?

As of 5 May 2023, the valuation grade for Owens & Minor, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market value. The company appears to be overvalued based on its current metrics, with a P/E ratio of 6, an EV to EBITDA of 4.76, and a PEG ratio of 0.14, which suggests limited growth prospects relative to its price. In comparison to peers, Owens & Minor has a higher P/E ratio than Pacific Biosciences of California, Inc., which has a P/E of -0.6779, highlighting a relative overvaluation. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -57.54% compared to the index's 12.22%. This stark contrast reinforces the notion that Owens & Minor, Inc. is currently overvalued in the market.